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A member of the M18 family of aspartyl aminopeptidases is
expressed by all intra-erythrocytic stages of the human malaria
parasite Plasmodium falciparum (PfM18AAP), with highest
expression levels in rings. Functionally active recombinant
enzyme, rPfM18AAP, and native enzyme in cytosolic extracts of
malaria parasites are 560-kDa octomers that exhibit optimal
activity at neutral pH and require the presence of metal ions to
maintain enzymatic activity and stability. Like the human aspar-
tyl aminopeptidase, the exopeptidase activity of PfM18AAP is
exclusive to N-terminal acidic amino acids, glutamate and
aspartate, making this enzyme of particular interest and sug-
gesting that itmay function alongside themalaria cytosolic neu-
tral aminopeptidases in the release of amino acids from host
hemoglobin-derived peptides. Whereas immunocytochemical
studies using transgenic P. falciparum parasites show that
PfM18AAP is expressed in the cytosol, immunoblotting experi-
ments revealed that the enzyme is also trafficked out of the par-
asite into the surrounding parasitophorous vacuole. Antisense-
mediated knockdown of PfM18AAP results in a lethal
phenotype as a result of significant intracellular damage and
validates this enzyme as a target at which novel antimalarial
drugs could be directed. Novel phosphinic derivatives of aspar-
tate and glutamate showed modest inhibition of rPfM18AAP
but did not inhibit malaria growth in culture. However, we were
able to draw valuable observations concerning the structure-
activity relationship of these inhibitors that can be employed in
future inhibitor optimization studies.
It is estimated that 3.2 billion people currently live in areas
where there is a risk of malaria transmission. Three to five hun-
dredmillion of these individuals become infected each year and
over two million die (1). The groups most affected by malaria
are children under five years of age and pregnant women in
sub-Saharan Africa. Parasite resistance tomost of the currently
used antimalarial drugs is now widespread and resistance to
newdrugs is developing (2).With an effective vaccine at least 15
years away there is an urgent need for new malaria treatments.
During the intraerythrocytic phase of development the par-
asite digests 65–75% of the host cell hemoglobin. A proportion
of this digested hemoglobin (16%) is used for protein synthesis
(3). Hemoglobin degradation is also important in reducing the
colloid-osmotic pressure within the infected erythrocyte,
which prevents premature cell lysis during parasite growth and
establishes a concentration gradient by which rare amino acids
enter themalaria-infected erythrocyte fromhost serum (4, 5, 6).
The degradation of hemoglobin to peptide fragments occurs
within a specialized acidic digestive vacuole (DV)9 by the action
of aspartic, cysteine, and metalloendoproteases and by dipepti-
dases. However, small peptide fragments are transported from
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theDV to the parasite cytosol where they are degraded into free
amino acids by amino- and carboxypeptidases (5).
There are eight aminopeptidaseswithin thegenomeof themost
clinically significant malaria species, Plasmodium falciparum
(www.plasmodb.org): fourmethionineaminopeptidases, twoneu-
tral aminopeptidases (leucine aminopeptidase (M17LAP) and
membrane alanine aminopeptidase (M1MAA)), a prolyl amin-
opeptidase (PAP), and an aspartyl aminopeptidase (M18AAP).
Using specific enzyme inhibitors, one of the methionine amin-
opeptidases has been validated in vitro and in vivo as a potential
drug target (7) and inhibitors of the M1MAA and M17LAP
have been shown to prevent malaria growth in culture (8).
Therefore, other aminopeptidases may also prove to be good
targets for new antimalarial agents, particularly as part of drug
combinations.
Aspartyl aminopeptidases are members of the M18 family
of metalloproteases (www.merops.sanger.ac.uk). Unlike the
methionine and neutral aminopeptidases, few aspartyl amin-
opeptidases (M18AAP) have been characterized; at present,
there is only limited information reported for the aspartyl
aminopeptidase ofmammals (9), yeast (10), and bacteria.10 The
lack of available substrate and inhibitor reagents has contrib-
uted to our poor understanding of the function of these
enzymes. However, because of their restricted specificities for
the N-terminal acidic amino acids, aspartic and glutamic acid,
which cannot be cleaved by any other aminopeptidases, they
are thought to act in concert with other aminopeptidases to
facilitate protein turnover. In humans, a more specific function
in the conversion of angiotensin II to the vasoactive angiotensin
III within the brain has been implicated (12).
Here, we report for the first time the physicobiochemical
properties, cellular expression, and distribution of the P. falcip-
arum aspartyl aminopeptidase (PfM18AAP). We have pro-
duced a functionally active recombinant form of the enzyme
that exhibits comparable properties to the native form meas-
ured in malaria cytosolic extracts. Our studies show that the
PfM18AAP is expressed in the parasite cytosol and exported to
the parasitophorous vacuole of the parasite indicating that
whereas the enzyme may function in the final stages of hemo-
globin digestion it may also have an additional function outside
the parasite. Antisense-mediated inhibition of the PfM18AAP
results in a lethal phenotype as a result of significant morpho-
logical changes to the parasite and, therefore, pinpoints the
enzyme as a promising target for new anti-malarial drug
development. However, novel inhibitors of aspartyl amin-
opeptidases that exhibit modest activity against the native
and recombinant PfM18AAP do not prevent the growth of
the parasites in culture.
EXPERIMENTAL PROCEDURES
Parasites and Preparation of Parasite Extracts—P. falcipa-
rum clone D10 was cultured as described (13). For experiments
investigating the stage-specific expression of PfM18AAP, para-
sites were synchronized using two rounds of sorbitol treatment
(14), and parasites harvested at ring, trophozoite, and schizont
stages.
After washing infected red blood cells in PBS, parasites were
released by incubationwith either (1) 0.03% saponin/PBS on ice
or (2) with 600 units/ml streptolysin O/PBS at 37 °C. Resulting
parasite pellets were washed three times with PBS, re-sus-
pended in 100 l of PBS, and extracted by two cycles of freeze-
thaw at80 °C followed by centrifugation at 14,000 g. Super-
natants were stored at20 °C.
Membrane preparations of infected red blood cells were pro-
duced by hypotonic lysis followed by centrifugation at 5,000
g (15). The crude membrane pellets were treated with 0.5 ml of
0.1 M sodium carbonate or 1 ml of 1% Triton X-100 and sepa-
rated into pellet and supernatant by centrifugation at 16,000
g. Proteins in the supernatant were concentrated by precipita-
tion with trichloroacetic acid (10% final concentration).
Production, Purification, and Characterization of Function-
ally Active Recombinant Aspartyl Aminopeptidase—The Plas-
moDB annotated gene sequence PFI1570c encoding the puta-
tive PfM18AAP was chemically synthesized by GENEART
GmbH (GeneArt, Germany) using codons for optimized gene
expression in the yeast Pichia pastoris. As reported by Stack et
al. (16) for the M17 leucine aminopeptidase, the malaria
PfM18AAP gene with the codons optimized for P. pastoris was
successfully expressed in a functional form in insect cells.
PotentialN-linked glycosylation sites were removed in gene syn-
thesis by replacing the asparagine of all Asn-X-Thr/Ser with Gln.
This construct was recombined with BaculoDirectTM C-terminal
linear DNA (Invitrogen) and transfected into Sf9 (Spodoptera fru-
giperda) cells (16). Like the M17 leucine aminopeptidase, the
malariaPfM18AAP genewhile synthesized in the codon style ofP.
pastoris, was not able to be expressed successfully in yeast (16).
For protein expression, Sf9 insect cells were infected at the
cell density 3  106 cells/ml with PfM18AAP recombinant
Baculovirus at a multiplicity of infection of 2–5 plaque forming
units/cell. rPfM18AAP,whichwas expressed bearing aHis6 tag,
was isolated from insect cells by affinity chromatography on a
Ni-NTA-agarose column as previously described (16). The
purity and molecular size of isolated rPfM18AAP was analyzed
using 12% reducing SDS-PAGE and gel filtration HPLC on a
Superdex-200 column using a Pharmacia Biotech Smart Sys-
tem. The mobile phase was PBS, the column was run at a flow
rate of 40 l per min, and 40-l fractions were collected.
The activity and substrate specificity of purified rPfM18AAP
was determined by measuring initial rates of hydrolysis of the
fluorogenic peptide substrates H-Asp-NHMec and H-Glu-
NHMec at an excitation wavelength of 370 nm and an emission
wavelength of 460 nm using a Bio-Tek KC4 microfluorimeter
(16). rPfAAP (60 nM) was incubated in 50mMTris-HCl, pH 7.5,
for 30 min before addition to the substrate. The pH profile for
rPfM18AAP activity was determined from the initial rates of
H-Asp-NHMec hydrolysis carried out in constant ionic
strength (I 0.1) with acetate/Mes/Tris buffers, pH 4–11 (17).
The pH stability was determined by incubating rPfM18AAP in
these buffers for 1 h at 37 °C before assaying for residual activity
at pH 7.5.
To investigate the effect of metal ions on enzymatic kinetic
parameters, rPfM18AAPwas incubatedwith variousmetal ions
for 30 min prior to initiation of the enzymatic reaction. Initial
rates were obtained at 37 °C over a range of H-Asp-NHMec10 T. Min and L. Shapiro, unpublished data.
P. falciparum M18AAP
30818 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 42•OCTOBER 19, 2007
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
substrate concentrations spanning Km (0.2–500 M) and at
fixed enzyme concentrations. The effect of bestatin, metal
chelators, and dithiothreitol on rPfM18AAP activity was inves-
tigated by measuring the initial rate of hydrolysis of 25 M
H-Asp-NHMec at pH 7.5 in the presence of each compound.
Each rate was compared with the control rate containing only
enzyme and substrate.
M18AAP activity in parasite extracts were determined by
first incubating aliquots of the extract in 50 mM Tris-HCl, pH
7.5, containing 1mMCoCl2 for 20min before addition to 25M
H-Asp-NHMec. Leucyl aminopeptidase activity in the extracts
was measured using 10 M H-Leu-NHMec as described (16).
PhosphorusContaining Inhibitors—Aseries of-phosphonic
(compounds 1, 4, 7, and 8) and -phosphinic (2 and 5) ana-
logues of acidic amino acids (18), as well as phosphinate dipep-
tides (3 and 6) (19) were tested for their inhibitory activity
toward PfM18AAP using the fluorogenic peptide assay
described above.
Polyclonal Antibody Production and Immunoblotting
Analysis—Polyclonal antiserumwas prepared against a 15-mer
peptide, C*FSHKENSQNKRDDQ, corresponding to amino
acid residues 211–224 of the putative P. falciparum aspartyl
aminopeptidase (PFI1570c) as described previously (20). Pro-
teins of saponin-lysed parasite extracts were resolved on reduc-
ing 10% SDS-PAGE gels, transferred to a nitrocellulose mem-
brane, and probed with the anti-PfM18AAP antisera (1:250
dilution) followed by a horseradish peroxidase-labeled anti-
mouse IgG antibody (1:5000 dilution, Chemicon International
Inc.) (21). The membrane was stripped and re-probed with an
anti-glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
rabbit antibody (1:5000 dilution) to demonstrate equal loading
and transfer of malaria proteins (22).
Fluorescence Microscopy—Fluorescence and phase-contrast
images were collected with an Axioscope 2 Mot (Zeiss)
equippedwith a Zeiss63/1.4 PlanApochromat lens. Live par-
asites were mounted in PBS and observed at ambient tempera-
ture. Parasite DNA was visualized by adding Hoechst dye (0.5
g/ml) and incubating at 37 °C for 10 min prior to mounting.
For indirect fluorescence, concanavalin A (0.5 mg/ml) was
added to each well of amultiwell slide and incubated for 30min
at 37 °C after which infected red blood cells were added, incu-
bated at room temperature for 15 min, and unbound cells were
removed by washing with PBS. The cells were fixed in 4% form-
aldehyde, 0.005% glutaraldehyde and probed with anti-
PfM18AAP antiserum orwith amousemonoclonal antibody to
GFPor c-myc (all diluted 1:500). Bound antibodywas visualized
with goat anti-mouse Ig-Cy2 (10 g/ml).
Transmission Electron Microscopy—Infected red blood cells
were fixed with 3% glutaraldehyde in cacodylate buffer, pH 7.2,
and processed according to standard methods (23). After
embedding in Spurr low viscosity resin, ultrathin sections
(50–60 nm thick)were prepared and stainedwith uranyl ace-
tate and lead citrate and examined with a JEOL 1200EX trans-
mission electron microscope operating at 80 kV.
Northern Blotting—Northern blotting was performed with
total RNA extracts prepared using TRIzol (Invitrogen) (21).
Blots were probed with a purified 1713-bp PCR fragment cor-
responding to the full-length CDS of the aspartyl aminopepti-
dase (PFI1570c) amplified from genomic P. falciparum DNA
using primers PFI1570ASF (ctgcagatggataagaaagctagggaa) and
PFI1570ASR (agatcttttgtcgtggacacatgtgga). Probes were
labeled with [-32P]dATP by random priming (DECAprime II,
Ambion Inc). The probe was hybridized overnight at 40 °C in a
hybridization buffer containing formamide (Northern Max;
Ambion). The filter was washed once at low stringency and
twice at high stringency (Northern Max; Ambion), then
exposed overnight.
For specific sense and antisense probes, 26 ng of the above
purified PCR product was primed with either a 3 primer (act-
tcgctaagagatcctatt) to generate a probe that specifically binds to
the endogenous mRNA or a 5 primer (atggttcgatagaagtttagg)
to produce a probe that binds specifically to the transgenic anti-
sense RNA. Geometric amplification of the PCR product was
performed using Taq polymerase under the following cycling
conditions: denaturing at 94 °C for 30 s, annealing at 50 °C for
30 s, followed by extension at 68 °C for 2 min, for 30 cycles.
These probes were hybridized to blots containing RNA
extracted from both D10 wild-type parasites and transgenic
cultures.
Construction of the Transgenic Expression Plasmids—
PFI1570cwas amplified from P. falciparum clone D10 genomic
DNA. The forward primer for PFI1570c was PFI1570F (agatc-
tatggataagaaagctagggaa) and contained a BglII restriction site
(in bold). The reverse primer was PFI1570R (ctgcagtttgtcgtg-
gacacatgtgga) and contained a PstI site (in bold). Antisense
primers were designed with restriction sites in the reverse ori-
entation (PstI forward and BglII reverse). The PCR products
were cloned into pGEM using a TA cloning system (Promega)
and sequenced to confirm that no Taq-associated errors had
occurred. In the case of GFP and c-myc constructs full-length
fragments were digested out of the pGEM vector using BglII
and PstI and subcloned into the GatewayTM compatible entry
vectors pHGFPB and pHcmycB (Gateway, Invitrogen) that had
previously been digested using BglII and PstI. Either a GFP tag
or a c-myc tag were ligated in-frame at the 3 end of the intro-
duced gene sequence, respectively (24). These introduced
genes were under the control of theHSP86 promoter. The anti-
sense sequence was cloned into the pHcmycB vector. These
entry vectors were designated pHB-PFI1570c-GFP and pHB-
PFI1570c-cmyc, respectively, whereas the antisense plasmid
was designated pHB-PFI1570-AS. Using those entry vectors
and GatewayTM compatible destination vectors with a destina-
tion cassette and a second cassette containing the human dihy-
drofolate reductase synthase gene under the control of the P.
falciparum calmodulin promoter as a selectable marker, clo-
nase reactions were then performed. These final plasmids
were designated pHH1-PFI1570c-GFPB (GFP tag), pHH1-
PFI1570c-cmycB (c-myc tag), and pHH1-PFI1570c-AS (anti-
sense). For transfection, ring stage parasites were subjected to
electroporation in the presence of 50 g of plasmid DNA as
described (25). Parasites resistant to WR99210 were obtained
up to 25 days later.
SequenceAnalysis—Aspartyl aminopeptidase proteases from
various specieswere retrieved from theNCBI data base. BLAST
hits were aligned using CLUSTAL W at PBIL and alignments
drawn using ESPrit 2.0.
P. falciparum M18AAP
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RESULTS
Interrogation of PlasmoDB Discovered a Putative Aspartyl
Aminopeptidase—PFI1570c, the putative aspartyl aminopepti-
dase of P. falciparum is located on chromosome 9 and as anno-
tated by PlasmoDB consists of a single open reading frame of
1713 bp that translates into a protein of 570 amino acids.
PFI1570c contains two signature domains, an N-terminal
aspartyl aminopeptidase domain (LAP4: residues 1–186, e
value 5e-34), and a C-terminal aminopeptidase 1 zinc metallo-
protease M18 domain (Peptidase_18: residues 246–556,
Pfam0217; e value 2e-47). The overall sequence identity
between the aspartyl aminopeptidases (M18AAP) of the vari-
ous rodent Plasmodium sp. is 61–65% and would be in the
region of 83–88% only for the fact that PfM18AAP possesses
two unique sequence insertions. These insertions, which are
predicted to form loops, are present in the central portions of
the enzymes and clearly do not prevent the enzyme from form-
ing an octomeric structure (see below). Whereas low levels of
identity exists between the PfM18AAP and the human (31%)
and yeast M18 aspartyl aminopeptidases (27%) the three histi-
dine residues (His-94, His-170, and His-440) that are predicted
from site-directed mutagenesis studies to be critical for enzy-
matic activity and another (His-352) essential for stabilization
of quaternary structure of human M18AAP are conserved and
are indicated in the alignment presented in supplementary
materials Fig. S1.
Biochemical Characterization of Functionally Active Recom-
binant rPfM18AAP—Recombinant rPfM18AAP was purified
from Baculovirus-transformed insect cells by affinity chroma-
tography on a Ni-NTA resin and resolved as a single protein
of 65 kDa in reducing SDS-PAGE (Fig. 1A). Purified
rPfM18AAP efficiently cleaved the simple fluorogenic sub-
strates H-Asp-NHMec andH-Glu-NHMecwith kcat/Km values
of 129.9 and 82.3 M1 s1, respectively (Table 1). The purified
enzyme exhibited aminopeptidase activity against the fluoro-
genic substrate H-Asp-NHMec between pH 6.0 and 9.0 with
optimal activity at pH 7.5 (Fig. 1B). The enzyme was stable
when stored for 1 h at 37 °C over the pH range 6 to 11. No
hydrolysis was observed against the fluorogenic substrates
H-Leu-NHMec, H-Phe-NHMec, H-Ala-NHMec, H-Pro-
NHMec, H-Gly-NHMec, H-Val-NHMec, H-Arg-NHMec, and
H-Ile-NHMec when the substrate concentration was 100 M.
rPfM18AAP activity was reduced to 14 and 8.3% after incu-
batingwith 10mMEDTA and 20mM o-phenanthroline, respec-
tively, demonstrating that metal ions are necessary for enzyme
activity (data not shown). A study of the effect of various metal
ions on the activity of the enzyme showed that it was enhanced
by Co(II), but not by Ca(II), Fe(II), Mg(II), Mn(II), and Ni(II),
whereas Zn(II) at a concentration of 1 mM abolished enzyme
activity (data not shown). When the enzyme was incubated for
30 min in 50 mM Tris-HCl, pH 7.5, and containing 1 mM Co(II)
the kcat/Km values of the enzyme for substrates H-Asp-NHMec
and H-Glu-NHMec increased 8- and 30-fold, respectively
(Table 1). These enzymekinetics studies showed that kcat values
increased while the Km values remained unchanged, which
indicates that the metal ion does not affect binding of the sub-
strate but does increase the catalytic efficiency of the enzyme.
PfM18AAP Activity in Soluble Extracts of Malaria Para-
sites—Activity against theM18AAP-specific substratesH-Asp-
NHMec andH-Glu-NHMecwas detected in soluble extracts of
malaria parasites and had similar characteristics to the activity
of purified rPfM18AAP. TheKm values with parasite extracts of
216 and 251 M for H-Asp-NHMec and H-Glu-NHMec,
respectively, are similar to the Km values of 327 and 136 M
obtained with rPfM18AAP for the same substrates (Table 1).
The specific activity (mol of NHMec released/min/mg of pro-
tein) for the enzyme in these extracts was 662.5 and 607 for
FIGURE 1. Purification of functionally active P. falciparum M18 aspartyl
aminopeptidase. A, purification of recombinant aspartyl aminopeptidase,
which bears a His6 tag, was performed using a Ni-NTA-agarose column and
monitored by 12% reducing SDS-PAGE. MW, molecular size markers; lane 1,
eluted purified rPfM18AAP fromNi-NTA-agarose column; lane 2, sample from
wash of Ni-NTA-agarose column; lane 3, column run-through of Ni-NTA-aga-
rose column; lane 4, soluble supernatant extract of insect cells; lane 5, insolu-
ble pellet of recombinant insect cells. B, hydrolysis of H-Asp-NHMec by
rPfM18AAPwasmonitoredover thepH range 4–11 in constant ionic strength
buffers (solid squares). Stability of the enzymewas investigated by incubating
the enzyme over the pH range 4–11 for 1 h at 37 °C and then assaying for
residual activity toward H-Asp-NHMec at pH 7.5 (open squares). C, analysis of
recombinant rPfM18AAP (large-dashed line) and soluble malaria parasite
extract (small-dashed line) by Superdex-200 HPLC column. Fractions were
assayed for enzyme activity using the fluorogenic peptide substrate H-Asp-
NHMec. The solid line represents the elution profile of molecular size stand-
ards, apo-ferritin (AF) (440 kDa), -amylase (-A) (232 kDa), bovine serum
albumin (BSA) (67 kDa), and carbonic anhydrase (CA, 29 kDa) monitored at
280 nm.
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H-Asp-NHMec and H-Glu-NHMec, respectively. Further-
more, the activity against these substrates was enhanced almost
10-fold by Co(II) but was not enhanced by other metal ions
studied (data not shown).
The molecular size of the rPfM18AAP and native enzyme in
parasite extracts were determined by HPLC size chromatogra-
phy by assaying fractions for activity toward H-Asp-NHMec.
H-Asp-NHMec-cleaving activity in parasite extracts eluted
from the HPLC molecular size column at the same retention
time as the activity of purified rPfM18AAP corresponding to a
molecular size of 560 kDa (Fig. 1C). The data suggest that both
native and recombinant PfM18AAP possess an octomeric
structure consistent with that observed for human M18AAP
(26).
PfM18AAP Is Transcribed and Translated in Intra-erythro-
cytic Stage Parasites—Northern blot analysis showed that wild
type D10 parasites transcribed a single species of mRNA with
an apparent size of 3 kb when hybridized using a 1713-bp
fragment comprising the complete CDS of the PfM18AAP (Fig.
2A). PfM18AAP appeared to be most abundantly expressed in
ring stage parasites (Fig. 2A).Western blot analysis showed that
when saponin-lysed parasite extracts of the same cultures were
probedwith anti-PfM18AAP antiserum a single protein species
with an apparent molecular mass of 65 kDa was observed,
which corresponded closely with the theoretical molecular
mass of 65.6 kDa (Fig. 2B).
Immunoblot analysis of soluble, peripheral membrane-
bound and integral membrane-bound fractions of isolated
malaria-infected erythrocytes showed that PfM18AAP was
exclusively associated with the soluble fraction (Fig. 3A). How-
ever, immunoblot analysis of saponin-lysed D10 parasite
extracts showed that the 65-kDa specieswas present in both the
parasite pellet (P1) and soluble fractions (S1) (Fig. 3B, panel i).
As saponin treatment permeabilizes both the erythrocyte and
the parasitophorous vacuole membrane (PVM) that surrounds
the parasite but not the parasite membrane itself these data
indicate thatPfM18AAP is expressed in the parasite cytosol and
is also exported out of the parasite. Immunoblots of streptolysin
O-lysed malaria-infected erythrocytes, which lyse the erythro-
cyte membrane but not the PVM, showed that the enzyme is
not transported into the erythrocyte cytosol but is retained
between the PVM and the parasite membrane (Fig. 3B, panel i,
S2 and P2). The data were further substantiated by probing the
same extracts with anti-GAPDH (Fig. 3B, panel ii), which is
known to be a cytosolic enzyme that is also secreted into the
space between the parasite and PVM (22).
Immunocytochemical Localization of PfM18AAP—Immuno-
fluorescence analysis of parasite-infected erythrocytes using
anti-PfM18AAP antibody located the PfM18AAP enzyme to
the parasite cytosol (Fig. 4A). The same staining pattern was
also seen with transgenic D10 parasites expressing a GFP-
tagged PfM18AAP probed with anti-GFP antibody confirming
that the enzyme is routed to the cytosol (Fig. 4B). In addition,
direct live fluorescence microscopy on these transgenic para-
sites also revealed a diffuse staining pattern characteristic of
localization to the parasite cytosol (Fig. 4C; immunoblots using
anti-GFP confirmed that parasites expressed a GFP-tagged
protein, data not shown). Staining with specific antisera was
TABLE 1
Kinetic parameters for the hydrolysis of
H-Asp-NHMec and H-Glu-NHMec by rPfM18AAP at pH 7.5 in the
presence and absence of cobalt
Substrate 1 mM Co Km kcat kcat/Km
M s1 M1 s1
Asp-NHMec  384.8 32.1 0.050 0.002 129.9
Asp-NHMec  327.3 2.2 0.354 0.008 1081.6
Glu-NHMec  135.1 15.6 0.011 0.0004 82.3
Glu-NHMec  136.3 8.7 0.33 0.006 2421.1
FIGURE 2. Expression of the P. falciparum M18AAP during intraerythro-
cytic development. A, total RNA isolated from stage-specific parasites frac-
tionated on a 1% Tris acetate-EDTA gel was probed with a DNA fragment
corresponding to the full-length aspartyl aminopeptidase DNA (i) and then
stripped and re-probed with a 28 S RNA probe to ensure equal sample load-
ing (ii). B, total protein extracted from stage-specific wild-type D10 parasites
as outlined above and probed with mouse anti-PfM18AAP antisera (i). The
membranes were stripped and re-probed with antibodies to P. falciparum
GAPDH to ensure equal sample loading (ii). Parasites were ring (R) stage, tro-
phozoite (T) stage, and schizont (S) stage.
FIGURE 3. Localization of the P. falciparumM18AAP in the infected eryth-
rocyte using immunoblotting. A, immunoblots of parasite soluble cytosolic
fraction (lane 1), peripheral membrane fraction (lane 2), integral membrane
fraction (lane 3), and insoluble fraction (lane 4).B, immunoblot ofD10malaria-
infected erythrocytes separated into a 14,000 g pellet (P) and supernatant
(S) fraction following saponin-lysis (1) and streptolysin-O-lysis (2). Immunob-
lots were probed with mouse anti-PfM18AAP antibody (i) or anti-GAPDH (ii).
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only seen in parasitized red blood cells as confirmed by nuclear
staining with Hoechst dye (Fig. 4, A–C) and no staining was
observed in wild-type D10 parasites (data not shown).
Transfection Experiments Confirm That PFI1570c Is the
Source ofM18AAPActivity inMalaria Parasites—The plasmid
pHH1-PFI1570c-cmycB was transfected into P. falciparum
clone D10 ring-stage parasites to establish transgenic parasites
with increased expression of PfM18AAP enzyme. Western
blots confirmed that tagged PfM18AAPwas expressed in this
transgenic line (Fig. 5A). In other experiments, parasites
were transfected with pHHI-PFI1570c-AS to knockdown
PfM18AAP enzyme expression. Northern blot analysis showed
that the antisense parasites transcribed a single species of
mRNA with an apparent size of 3 kb when hybridized with
either a double-stranded probe or a single-stranded sense
probe. This was slightly larger than in the parental line D10.
When probed with a single-stranded antisense probe the trans-
fected parasites transcribed a single species of mRNA with an
apparent size of3 kb (Fig. 5B).
Soluble extracts of cultured wild-type and transgenic para-
sites were assayed for PfM18AAP activity using the substrate
H-Asp-NHMec. Extracts derived from the pHH1-PFI1570c-
cmycB-transfected parasites exhibited a 4-fold higher
PfM18AAP activity than D10 control extract. In contrast,
pHHI-PFI1570c-AS-transfected parasites showed 80-fold
lower activity than D10 control extracts (Fig. 5C). As a control,
we measured the activity of a previously characterized amino-
peptidase, a M17 leucyl aminopeptidase (M17LAP), with the
substrate H-Leu-NHMec (16) and demonstrated that this was
expressed at similar levels in the wild-type and the two trans-
genic D10 parasite lines (Fig. 5C). No aspartyl activity was
detected in extracts of uninfected erythrocytes.
Transfection with Antisense Plasmid pHHI-1570c-AS
Induces Cellular Damage—To examine whether inhibition of
PfM18AAP enzyme expression in the parasite transfected with
the plasmid pHHI-1570c-AS had an effect on parasite develop-
ment these were selected with 5 nM WR99210 and maintained
in culture. To increase the copy number of the plasmid the
parasites were then further selected with 10 nM (2 times)
WR99210. Significant cellular alterations were observed by
electronmicroscopy of the transgenic parasite cultures selected
on 2WR compared with wild-type D10 parasites. Of partic-
FIGURE 4. Cytochemical localization of the P. falciparumM18AAP. A, indi-
rect immunofluorescence of D10 wild-type parasites probed with polyclonal
antisera to native PfM18AAP. B, indirect immunofluorescence of PFI1570c-
GFP transgenic parasites probed with specific antisera to GFP. C, direct fluo-
rescence on live PFI1570c-GFP transgenic parasites. Parasite nucleiwere visu-
alizedwithHoechstdye (blue). Specific stainingwasobserved in the cytosol of
the ring and schizont stage parasites (green, fluorescein isothiocyanate).
FIGURE 5. Overexpression and antisense-mediated knock-down of
M18AAP inP. falciparummalariaparasites.A,wild-typeD10parasiteswere
probedwithmouse polyclonal anti-PfM18AAP. Transgenic parasites express-
ingPFI1570c-cmycwere assessedby immunoblot analysis using specific anti-
c-myc antibodies, respectively. B, knockdown of the P. falciparum aspartyl
aminopeptidase gene. Northern blot using total RNA isolated fromD10wild-
typeparasites andPFI1570c-antisense transgenic parasites (AS). This blotwas
probed sequentially with panel i. A randomly primed probe that will detect
both sense and antisense strand. Panel ii, a probe generated to detect the
sense strands. Panel iii, a probe generated to detect the antisense strand.
Panel iv, reprobed with the P. falciparum 28 S RNA probe to ensure equal
sample loading. C, comparison of PfM18AAP activity between control para-
sites (D10), parasites overexpressing PfM18AAP (1570 c-myc), and parasites
with antisense-mediated knockdown of PfM18AAP expression (1570 AS).
ActivitywasmeasuredusingH-Asp-NHMec and expressed asmillifluorescent
units/mg of protein (mFU/mg protein). Data shown are the average of results
from two separate knock-down experiments. RBC, red blood cell.
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ular note was rupture of the food vacuole in ring and schizont
stages (Fig. 6A, panels i and iv) as well as accumulation of large
lipid droplets (Fig. 6A, panel iii) and accumulation of hemoglo-
bin (Fig. 6A, panel ii) in trophozoites. These changes were not
seen in wild-type D10 parasites (Fig. 6B) or in parasites trans-
fected with the pHH1-PFI1570c-GFPB plasmid cultured under
the same regime (Fig. 6C).
Inhibition of PfM18AAP by Phosphorus Containing Inhibi-
tors—Several -phosphonic (compounds 1, 4, 7, and 8, Fig. 7),
-phosphinic (2 and 5), and phosphinate dipeptides (3 and 6)
were tested for their inhibitory activity toward PfM18AAP.
Their structures are shown in Fig. 7 and the inhibitory activity
presented in Table 2. The compounds are best described as
moderate inhibitors of the enzyme; however, valuable observa-
tions concerning the structure-activity relationship of these
inhibitors could be drawn. First, a strong preference for the
glutamate side chain is clearly visible. The most active, phos-
phonic analogue of glutamate (compound 4, tested in the form
of the pure enantiomer R, corresponding to the relative config-
uration L, exhibited a Ki of 0.34 M) appeared between 2 and 3
orders of magnitude more potent than the homologues shorter
and longer by a single methylene group (compounds 1 and 8),
respectively. This observation is also supported by the quite
unexpected high activity of compound 7, which represents an
analogue of glutamic acid with two carboxylic groups being
replaced by the phosphonic moieties. Second, although the
difference in inhibitory activity for AspP[CH2]Ala and
GluP[CH2]Ala dipeptide analogues (see 3 versus 6) was less
significant, the latter substrate was 3-fold more potent, which
agrees with our studies using fluorogenic substrates that
showed Glu is accepted in the P1 site of PfM18AAP more
readily than Asp (Table 1). Third, a meaningful, albeit some-
what surprising, observation was the decrease of inhibitor
potency in any attempts of inhibitor elongation by the intro-
duction of a P1 substituent. Thus, neither the P-modified
phosphinic amino acid analogues nor the phosphinic dipep-
tides retained the activity exhibited by the simplest phosphonic
amino acid derivatives (compare 1 versus 3 and 4 versus 6, for
example).
Activity of Phosphorus Containing Inhibitors Against
Malaria Parasite in Vitro—The inhibitors described above did
not exhibit any significant inhibition of the growth of P. falcip-
arumD10 parasites in culture (even at 100 M final concentra-
tions) using methods described previously (16).
DISCUSSION
The number of gene sequences in the public data bases that
encode members of the M18 aspartyl aminopeptidase family
aremounting due to genomic sequencing projects, but previous
to the present study only two members have been biochemi-
cally characterized, those derived from human (9) and yeast
(10). In fact, because the yeast enzyme, referred to as yeast
aminopeptidase I, exhibits a preference for leucine over acidic
amino acid residues and lacks a well conserved His-352, Wilk
FIGURE 6. Electronmicroscopic images of transgenic antisenseparasites.
Parasitized red blood cells were fixed with glutaraldehyde fixative solution
and embedded in Spurr low viscosity resin. Ultrathin sections were stained
with uranyl acetate and lead citrate and examined with a JEOL 1200EX trans-
mission electron microscope. A, electron microscopic images of transgenic
antisense parasites PFI1570cAS showing damage with the malarial cell such
as rupture of cell compartments in ring (panel i) and schizont stages (panel iv)
and accumulation of hemoglobin (panel ii) and lipid drops (panel iii) in late
trophozoites.BandC, electronmicroscopic imagesofwild-typeD10parasites
andD10 parasites transfected PFI1570c-GFP, respectively, that were cultured
under similar conditions; these parasites show normal morphology.
FIGURE 7. The structures of phosphorus containing phosphonic and
phosphinic analogues of acidic amino acids and dipeptides used as
inhibitors against PfM18AAP.
TABLE 2
Ki values for the inhibition of rPfM18AAP by -phosphonic
(compounds 1, 4, 7, and 8), -phosphinic (2 and 5) and phosphinate
dipeptide (3 and 6) derivatives of Asp and Glu at pH 7.5
Inhibitor Ki
M
1, AspP 27.1
2, AspP-Me 395
3, AspPCH2	Ala 183.1
4, (R)-GluP 0.34
5, GluP-Ph 
2000a
6, GluPCH2	Ala 42.7
7, GluP2 4.4
8, APPA 105
aOnly 20% inhibition when I	  1.83 mM.
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et al. (26) suggested that it was not a true M18 aspartyl amino-
peptidase; a second sequence Yhr113wp, which does possess the
conserved His-352, is now considered the genuine yeast
M18AAP (10) (see supplementary materials Fig. S1). The P.
falciparum PFI1570c gene is located on chromosome 9 and
encodes an enzyme with conserved N- and C-terminal domains
typical of theM18AAP family, retains the conserved His-352 and
possesses three other histidine residues (His-94,His-170, andHis-
440) that were shown by Wilks et al. (26) using site-directed
mutagenesis to be essential for enzymatic activity of the human
M18AAP. Because the M18AAP peptidases lack the typical
HEXXH zinc-binding motifs found in other metalloaminopep-
tidases it was postulated that His-94, His-170, and His-440
coordinate the active site zinc metal ions in this family of
enzymes (26). Our biochemical investigations of native and
recombinant malarial aspartyl aminopeptidase demonstrated
that the enzyme requires metal ions for its activity and has a
strict preference for N-terminal acidic amino acids, glutamate
and aspartate (the enzyme failed to cleave hydrophobic, basic or
neutral amino acids) and, thus, we can confidently place it
among the M18AAP family. Uniquely, the PfM18AAP pos-
sesses two large sequence insertions in the central portion of
the molecule, but given the fact that we could produce a func-
tionally active recombinant enzyme that retains these inserts
they clearly do not affect the formation of the multimeric qua-
ternary structure of the enzyme or the structure of its active
site. In the absence of a three-dimensional structure for the
M18AAPs we cannot determine how these insertions are
arranged in space but because they are predicted to be loops
they presumably emanate freely from the core structure of the
molecule. Furthermore, because they are absent from the
homologous enzymes expressed in another human malaria, P.
vivax, and in several rodent malarias, they are not suspected to
play a critical role in enzyme function.
Our cytochemical studies with wild-type and transgenic
malaria parasites revealed that the PfM18AAP is routed to and
expressed in the cytosol of the parasite. We recently described
another malaria aminopeptidase, a M17 leucine aminopepti-
dase (16) (M17LAP), with exopeptidase specificity for N-termi-
nal hydrophobic residues, Leu and Phe, that was also localized
in this compartment. Accordingly, as has been suggested to
take place in mammalian cells (9, 26), the two enzymes may
function in concert in protein catabolism. The catabolic pro-
cesses they are likely involved in, include the breakdown and
turnover of malaria cellular proteins and the release of amino
acids from peptides that are generated from the digestion of
host hemoglobinwithin themalaria DV. The latter peptides are
transported from the DV to the cytosol for final processing to
free amino acids that are used in the anabolism of proteins
required for the rapidly growing intracellular parasite.
PfM18AAP would be necessary for tackling the acidic amino
acids, Glu and Asp residues, which comprise 8% of the total
amino acid content of hemoglobin and cannot be removed by
PfM17LAP (16). Earlier studies by us (27) implied the presence
of these two aminopeptidase classes in malaria because cytoso-
lic extracts could effectively cleave hemoglobin-derived pep-
tides containing hydrophobic and acidic amino acids in their
sequence. However, these studies also inferred the presence of
additional aminopeptidases that could remove amino acids
such as alanine, lysine, valine, and proline that are not cleaved
by the PfM18AAP or PfM17LAP. Two other aminopeptidases
identified in the malaria genome, an M1 membrane alanyl
aminopeptidase (M1MAA) and a prolyl aminopeptidase, can
putatively cleave these amino acids and, therefore, complete the
line-up of exopeptidases required for the total degradation of
hemoglobin to free amino acids in the parasite cytosol.
More specific functions for humanM18AAP are emerging in
the literature and include processing of biologically active pep-
tides with N-terminal Asp or Glu such as -amyloid peptide,
angiotensin II, cholecystokinin, and neuromedin (see Ref. 26).
The PfM18AAP is also secreted outside the parasite and into
the space between the parasite plasma membrane and the sur-
rounding parasitophorus vacuole membrane, i.e. into the para-
sitophorus vacuole, but not to the erythrocyte cytosol. Mole-
cules passing into the parasite from the exterior, and vice versa,
must pass though this space in which the parasite sits. Accord-
ingly, we could speculate that the PfM18AAP has some role in
processing proteins or peptides in transit in either direction,
but presently we have no candidate substrates. Additionally, or
alternatively, the enzymemay have a role to play in cell rupture
and the release of merozoites by the processing of other mole-
cules; again, we have not identified any particular host or para-
site protein or peptidewith anN-terminal Glu orAsp and puta-
tive function in cell rupture. Using P. falciparum phage display
libraries Lauterback et al. (28) identified 7 proteins, including
PfM18AAP, that bind to the erythrocyte cytoskeletal proteins
spectrin and band 4.1 and may be involved in structurally re-
organizing these during either the invasion or exit of the para-
sites. There are a number of malaria proteins that exist in the
PV for which functions are unclear, however, others such as
GAPDH are known housekeeping enzymes (22). The putative
serine protease ABRA (29) and the SERA/SERPH family of ser-
ine protease-like molecules have been shown to localize to the
parasitophorous vacuole (30) and have been postulated to play
a part in parasite egress but their exact role remains to be deter-
mined (31).
To investigate the essential nature of the PfM18AAP in P.
falciparumwe created a knockdown-transgenic parasite line by
transfecting parasites with an antisense plasmid. This antisense
inhibition technique was recently developed for P. falciparum
in our laboratory (32) given that knockdown by RNA interfer-
ence is generally considered ineffective in this organism (33). As
antisense inhibition results in a knockdown of protein expres-
sion it also offers an alternative to knock-out of gene function
and, therefore, the method can be employed to evaluate the
importance of a gene product in parasite function and survival.
In the present study the technique was demonstrated to suc-
cessfully knockdown the expression of PfM18AAP activity
because the transgenic parasites exhibited 80-fold less enzyme
activity compared with wild-type parasites. The method was
also highly target-selective as the relative activity of the malaria
cytosolic M17LAP was shown to be unaffected by knocking
down the PfM18AAP. Together with the data showing that
overexpression of the PfM18AAPby transfecting parasites with
the plasmid pHH1-PFI1570c-cmycB resulted in an increase of
M18AAP activity, these knockdown results prove that the
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PFI1570c gene encodes the M18AAP activity in malaria para-
sites. More importantly, antisense-mediated knockdown of
PfM18AAP resulted in a lethal phenotype from significantmor-
phological damage. The damage was not restricted to the
cytosol of the parasite but was also observed in theDV, which is
not surprising if by blockingPfM18AAP expression general cel-
lular protein anabolism is hampered or prevented.
The antisense knockdown experiments validate the
PfM18AAP as an anti-malarial target, and, therefore, we sought
to identify potential lead inhibitor compounds. Our previous
studies have shown that phosphinic analogues of substrate-like
dipeptide analogues are the most potent inhibitors of leucine
aminopeptidases, including the PfM17LAP, and that these
exhibit potent anti-malarial activity in culture (16, 34). Their
potency is governed by their ability to fit within the active site of
the enzyme and to chelate the co-catalytic zinc metal ions.
Given that the PfM18AAP is also a zinc metalloexoprotease we
tested a selection of-phosphonic,-phosphinic, and phosphi-
nate derivatives of the amino acids Asp and Glu. The particular
inhibitors employed here have been previously used as tools to
investigate the active site of other aminopeptidases (18, 19),
although this is the first report on their activity against aspartyl
aminopeptidases. Consistent with our substrate binding analy-
sis, derivatives of Glu proved to be themost potent inhibitors of
PfM18AAPbut, surprisingly, attempts to extend their structure
with a P1Ala to induce binding in the S1 and S1 subsites of the
enzyme resulted in a reduction rather than an increase in their
potency. Overall, the inhibitors exhibited modest activity and
did not show a significant blocking effect on malaria parasite
growth in culture. However, several studies have reported that
the in vitro anti-malaria activity (IC50) of inhibitors are often in
the region of 3-fold orders of magnitude greater than their
inhibitory constants (Ki) against free enzymes (16, 35), presum-
ably, because the inhibitor needs to cross several membrane
barriers (erythrocyte, PVM, and plasma membrane) to gain
access to its target enzyme. Therefore, further studies on the
substrate preferences of the PfM18AAP, particularly in the S1
subsite, are important to guide structural optimization of the
compound series presented herewith a view to obtaining inhib-
itorswith potency onparwith our anti-PfM17LAPphosphinate
dipeptide analogs (16). To this end, -phosphonoglutamic acid
(4) seems to be an attractive lead (Ki 0.34 M) to build upon.
Our studies add further endorsement for the idea that amino-
peptidases ofmalaria are tractable targets for anti-malarial drug
development. The production of these enzymes as functionally
active recombinants and the development of simple robust
assays for measuring inhibitor potency will allow progress to
screening of high-throughput chemical libraries for novel
inhibitors with lead-like characteristics. This strategy has
already been successfully applied by Chen et al. (7) who identi-
fied a family of structurally related compounds with a common
2-(2-pyridinyl-pyrimidine) core that selectively blocked
malaria methionine aminopeptidase 1b (PfMetAP1b) activity
and exhibited activity against rodent malaria models in vivo. It
is plausible that compounds, or a combination of compounds,
could be designed to simultaneously inhibit the various classes
of aminopeptidases and thus develop a treatment that is less
likely to be negated by the emergence of drug-resistant para-
sites. Given that the PfMetAP1b, PfM17LAP, PfM1MAA, and
the PfM18AAP possess an active site scaffold that binds metal
ions (which activate the H2O to form an hydroxide nucleophile
that attacks the peptide bond) it may be judicious to exploit this
in future multiple-target anti-malaria drug design. Further-
more, there is a precedent for this approach because drugs that
target themetal center of metalloproteases such asmatrixmet-
alloproteases, tumor necrosis factor- converting enzyme, and
histone deacetylace have been successfully used in treating can-
cer and arthritis (11, 36).
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Fig. 7. The structures of phosphorus containing phosphonic and phosphinic analogues of acidic 
amino acids and dipeptides used as inhibitors against PfM18AAP. 
 
Supp. Fig. 1. Comparison of the deduced amino acid sequence of the P. falciparum M18AAP 
with related sequences from other malaria species, human and yeast. The sequences, Plasmodium 
falciparum (PFI1570c), P. vivax (PV087090), P. c. chabaudi (PC_R0262), P. yoelii (MALPY00917), 
Homo sapiens (Q9LUA0), and Saccharomyces cerevisiae (Yhr113wp) were aligned using ClustalW 
program. Conserved amino acids sequences are in white within a black background. The conserved 
putative active site histidines residues are indicated by black triangles, and the histidine suggested to be 
involved in stabilising the quaternary structure of human M18AAP is indicated by an open triangle. 
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